The Ohio State University and Battelle Partner to Establish new NeuroTech Institute to Help Advance Neurolgical Research and Treatment

The Ohio State University and Battelle have partnered to launch an independent state-of-the art neurotechnology accelerator focused on treatments for patients with neurological disorders.

Neurological disorders affect 1-in-6 individuals worldwide according to the United Nations. Existing treatments fail to restore health to many, and promising new treatments face a long and complex path to market.

The new NeuroTech Institute (NTI) will accelerate the pace of progress. A biotechnology accelerator, NTI houses three unique programs focused on disorders of neural communication, the neural genome, and the network of the mind. It is already working on technology advancements to help individuals dealing with paralysis from spinal cord injury.

NTI is the result of years of preparations by Ohio State and Battelle and uses a collaborative approach to science—uniting clinicians, engineers, and patient advocates to pioneer new treatments.

NTI is recruiting faculty, researchers, and support staff, which will add to the depth of expertise of already existing faculty across Ohio State and Battelle.

“This new institute complements Ohio State’s efforts to build new opportunities for interdisciplinary research, translation and partnerships and accelerate solutions for patients with neurological disorders,” said Peter Mohler, PhD, Vice President for Research at Ohio State.

Battelle Executive Vice President of Applied Science and Technology, Matt Vaughan said, “By partnering with Ohio State and combining our resources, skills and vision we will be able to bring speed, creativity and expertise to bring world-changing neurotechnology solutions. Ohio State brings breakthrough foundational science, Battelle brings advanced development and applied science and technology, and the Institute brings the accelerator and philanthropic elements.”

Tim Lucas, MD, PhD, MHCI, professor of neurological surgery at Ohio State’s College of Medicine, was recruited to be NTI’s inaugural chief executive officer. Lucas brings four large awards from the National Institutes of Health as well as sponsored research agreements from government and industry to the new institute.

“At NTI, our mission is to restore quality of life to those suffering from neurological diseases, such as dementia, epilepsy, and addiction. Through our innovations, we will ensure that patients benefit from new treatments as quickly as possible,” Lucas said.

More information on NTI may be found at https://neurotechinstitute.org

About The Ohio State University

The Ohio State University is a world-class flagship public research university with a nationally recognized academic medical center. The university offers more than 200 majors — plus 500 specializations— for undergraduates to explore, along with 230 master’s, doctoral and professional degree programs. Across all campuses, Ohio State enrolls nearly 68,000 students in 15 colleges and supports more than 300 academic and interdisciplinary research centers and institutes. With a dynamic and engaged group of more than 580,000 living alumni and extensive partnerships locally and globally, Ohio State has an unparalleled capacity to bring people together and provide expertise and resources to find solutions to the problems the world is facing now.

About Battelle

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005513/en/